Freshly Printed - allow 7 days lead
Couldn't load pickup availability
Lung Cancer
Jack A. Roth (Edited by), JA Roth (Author), Waun Ki Hong (Edited by), Ritsuko U. Komaki (Edited by)
9781118468746, Wiley
Hardback, published 23 May 2014
616 pages
24.4 x 19.3 x 3.3 cm, 1.361 kg
“With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.” (Kingbook73's Medical Ebook and Video Collection, 19 September 2014)
The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded. Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever –featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more. This Fourth Edition of Lung Cancer: With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.
Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.
Contributors, viii Preface, xiii 1 Smoking Prevention and Cessation, 1 2 Lung Cancer Susceptibility and Risk Assessment Models, 25 3 Molecular Profiling, 48 4 Somatic Genome Alterations in Human Lung Cancers, 67 5 Serum Proteomic Biomarkers, 90 6 Molecular Biology of Lung Preneoplasia, 110 7 Detection and Treatment of Preneoplastic Lesions, 129 8 Pathology of Adenocarcinoma, 144 9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158 10 Radiology and Lung Cancer Screening, 176 11 Imaging Lung Cancer, 191 12 Staging of the Mediastinum, 202 13 Management of the Solitary Pulmonary Nodule, 214 14 Minimally Invasive Resections for Lung Cancer, 224 15 Extended Resections for Lung Cancer, 236 16 Bronchoscopic Interventions for Lung Cancer, 253 17 Primary Tracheal Tumors, 267 18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278 19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290 20 Image-Guided Radiation Therapy, 309 21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320 22 Proton Therapy, 338 23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353 24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379 25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390 26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406 27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421 28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435 29 Immunologic Approaches to Lung Cancer Therapy, 454 30 Novel and Emerging Agents in NSCLC, 464 31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479 32 Novel Statistical Models for NSCLC Clinical Trials, 488 33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505 34 Anti-angiogenic Agents in Metastatic NSCLC, 527 35 Targeting ALK Rearrangements, 541 36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557 37 Prognostic and Predictive Biomarker Signatures, 564 38 Brain Metastasis from Lung Cancer, 572 Index, 591 Color plate section between pages 146 and 147
Alexander V. Prokhorov and Karen Suchanek Hudmon
Xifeng Wu, Xia Pu, and Jie Lin
Lauren Averett Byers
Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson
Mohamed Hassanein and David P. Carbone
Humam Kadara and Ignacio I. Wistuba
Rachel Jen and Stephen Lam
William D. Travis
Howard West
Patricia de Groot and Reginald F. Munden
Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus
Mauricio Pipkin and Shaf Keshavjee
Min P. Kim
Shanda H. Blackmon
Matthew A. Steliga and David C. Rice
Donald R. Lazarus and George A. Eapen
Francesco Sammartino and Paolo Macchiarini
Kathryn A. Gold
Christopher G. Azzoli and Katherine M.W. Pisters
Kenneth E. Rosenzweig and Sonal Sura
Puneeth Iyengar and Robert D. Timmerman
Joe Y. Chang and James D. Cox
Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki
Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox
Steven H. Lin and Ritsuko U. Komaki
Kathryn F. Mileham, Edward S. Kim, and William N. William Jr
Erminia Massarelli
Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao
Jay M. Lee, Steven M. Dubinett, and Sherven Sharma
Anne S. Tsao and Jack A. Roth
Vassiliki A. Papadimitrakopoulou
J. Jack Lee and Caleb T. Chu
John V. Heymach and Tina Cascone
Millie Das and Heather Wakelee
Justin F. Gainor and Alice T. Shaw
Renata Ferrarotto and George R. Simon
Johannes R. Kratz and David M. Jablons
Ritsuko U. Komaki and Amol J. Ghia
Subject Areas: Clinical & internal medicine [MJ]
